Most Searched
Originally published November 17, 2026
Last updated November 17, 2026
Reading Time: 3 minutes
Search more articles
News & Magazine
Topics
Transoral robotic surgery (TORS) has emerged as a powerful tool in the management of oropharyngeal squamous cell carcinoma (OPSCC), particularly for the growing population of HPV-associated cancers. But identifying which patients are ideal candidates for TORS requires careful evaluation — and a low threshold for referral, according to head and neck cancer surgeon Niels C. Kokot, MD, the new director of the USC Head and Neck Center, which includes experts from the USC Caruso Department of Otolaryngology – Head and Neck Surgery and the USC Norris Comprehensive Cancer Center of Keck Medicine of USC.
“The indications for TORS are typically early-stage cancers — T1 and T2 — and, in some situations, T3 cancers may be acceptable,” Kokot says. “Larger tumors, such as T4 cancers, will be poor candidates.” However, he notes that in certain situations, more advanced cancers may still be considered on a case-by-case basis.
The majority of oropharyngeal cancers seen today are HPV-associated, and these patients tend to have excellent oncologic outcomes — roughly 90% cure rates. “Because most of these patients are going to live a long, healthy life, there’s a huge need to treat them effectively with as few side effects as possible,” Kokot explains. “We don’t want to burden them with undue side effects from overtreatment.”
For early-stage disease, both surgery and radiation are viable options. The goal is to avoid using all three modalities — surgery, radiation and chemotherapy — when possible. “We try to do either surgery with or without radiation, and avoid chemotherapy, or we’ll try to do chemo and radiation and avoid surgery,” Kokot says.
The advantage of surgery for smaller tumors is that some patients can avoid radiation altogether. In other cases, radiation can be de-escalated from seven weeks to five weeks. “That has a significant benefit to patients for their functional outcomes,” he notes.
While staging is important, tumor location is equally critical. “When the tumor is confined to the tonsil or the base of tongue, generally those are good candidates,” Kokot says. However, tumors that extend into the soft palate, even if technically T1 or T2, may not be ideal for TORS.
“Those patients will have a lot of velopharyngeal insufficiency postoperatively if we do robotic surgery, and it’s more difficult to reconstruct the soft palate area,” he explains. “In those situations, we consider doing a free flap, even with robotic surgery. Sometimes those patients are better candidates for radiation.”
Traditional open approaches for oropharyngeal cancer often required splitting the jaw and performing free-flap reconstruction, with significant morbidity and prolonged recovery. “Most of those patients were getting a trach tube and a G-tube,” Kokot says. “By doing robotic surgery, we’re going through the mouth, avoiding the lip split and jaw split. No free flap is typically required, and patients have a much quicker return of swallow function.”
Kokot emphasizes that when in doubt, community physicians should refer their oropharyngeal cancer patients to specialists. “Sometimes the scans may not tell the whole picture, and we can determine whether they’re going to be a better candidate for surgery or radiation-based treatment,” he says. “It’s sometimes difficult to tell unless we’re actually seeing the patient and able to examine them and their tumor.”
For patients with early-stage oropharyngeal cancer — particularly those with HPV-associated disease and tumors confined to the tonsil or base of tongue — referral to a high-volume center like Keck Medicine ensures access to TORS and a multidisciplinary team that can tailor treatment to each patient’s anatomy and goals, thus optimizing outcomes.
Share